Loading…
for educational and safety purposes
Mazdutide and Cagrilintide both come up in the same conversations; they overlap on Appetite. Mazdutide: Mazdutide (IBI362, LY3305677) is an investigational once-weekly peptide that simultaneously activates the glucagon-like peptide-1 (GLP-1) and glucagon receptors, a dual-agonist design intended to combine appetite suppression and improved glycemic control from the GLP-1 arm with increased energy expenditure and hepatic lipid handling from the glucagon arm. Cagrilintide: Cagrilintide is a next-generation, long-acting amylin analogue engineered for once-weekly dosing and sustained appetite control.
Mazdutide (IBI362, LY3305677) is an investigational once-weekly peptide that simultaneously activates the glucagon-like peptide-1 (GLP-1) and glucagon receptors, a dual-agonist design intended to combine appetite suppression and improved glycemic control from the GLP-1 arm with increased energy expenditure and hepatic lipid handling from the glucagon arm. In Chinese phase 3 obesity trials it produced substantial, dose-dependent weight loss, with the GLORY-2 study reporting roughly 16 percent mean body-weight reduction at the 9 mg dose, alongside favorable changes in blood pressure and lipids. In type 2 diabetes it lowered glycated hemoglobin and body weight more than the GLP-1 monotherapy dulaglutide, and it improved fatty liver and cardiometabolic markers. Gastrointestinal effects such as nausea, vomiting, and diarrhea are the most common adverse events, consistent with its incretin mechanism.
Cagrilintide is a next-generation, long-acting amylin analogue engineered for once-weekly dosing and sustained appetite control. In clinical trials it has driven substantial weight loss on its own and even greater results when paired with semaglutide, placing it among the most promising agents in modern metabolic medicine. For those pursuing serious, science-backed weight management, cagrilintide represents a genuinely novel and powerful mechanism.
both fingerprints on one instrument; where the marks line up the two compounds work the same lever, where a slot goes dark only one of them touches it. read straight from each entry's affinity table; nothing here is invented.
Reduction
Agonist
Agonist
long-acting agonist
lowers
slows
strengths are the entries' qualitative ratings (strong / moderate / weak); Ki and EC50 figures appear where an entry records them.
easiest to source: Cagrilintide is currently listed by more trusted vendors (3), so it's the simpler one to get hold of. for effects and safety, read each full entry; this is educational, not medical advice.